trans-4-(Trifluoromethyl)cinnamic acid

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
279.2±35.0 °C at 760 mmHg

[ Melting Point ]:
231-233 °C(lit.)

[ Molecular Formula ]:
C₁₀H₇F₃O₂

[ Molecular Weight ]:
216.157

[ Flash Point ]:
122.6±25.9 °C

[ Exact Mass ]:
216.039810

[ PSA ]:
37.30000

[ LogP ]:
3.37

[ Vapour Pressure ]:
0.0±0.6 mmHg at 25°C

[ Index of Refraction ]:
1.526

Click to get detail MSDS

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi: Irritant;

[ Risk Phrases ]:
R36/37/38

[ Safety Phrases ]:
S26-S37/39

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ HS Code ]:
2916399090

Precursor

DownStream

[ HS Code ]: 2916399090

[ Summary ]:
2916399090 other aromatic monocarboxylic acids, their anhydrides, halides, peroxides, peroxyacids and their derivatives VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%

Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.

Drug Metab. Dispos. 37(10) , 2061-8, (2009)

Leflunomide is a disease-modifying antirheumatic drug used for the treatment of rheumatoid arthritis (RA). Cytochromes P450, mainly CYP1A2 and CYP2C19, may be involved in the transformation of lefluno...

More Articles